摘要
目的分析奥沙利铂联合肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效。方法选取58例原发性肝癌患者,随机分为2组,对照组29例单独使用TACE治疗;观察组29例奥沙利铂联合TACE进行治疗,检测两组患者治疗前和治疗2周后血清中TNF-α、AFP、WBC、CEA水平及肿瘤直径的变化,并记录治疗总有效率和不良反应发生情况,统计患者的生活质量和满意度。结果治疗后观察组TNF-α、AFP、CEA水平、肿瘤直径分别为(11.25±1.14)μg/L、(289.97±10.32)μg/L、(100.49±11.43)μg/L、(3.87±0.79)cm,各指标均减少,白细胞数目(5.08±1.31)×109个,几乎没有变化。与对照组比较,差异有统计学意义(P<0.05),且观察者患者治疗总有效率、生活质量、患者满意度均比对照组高,不良反应发生率较对照组偏低,差异有统计学意义(P<0.05)。结论奥沙利铂联合TACE可提高患者治疗总有效率、生活质量和满意度,降低不良反应发生率,疗效确切,安全有效,值得在临床推广。
Objective To analyze clinical efficacy of oxaliplatin combined with transcatheter arterial chemoembolization （TACE） in treatment of primary liver cancer. Methods Fifty-eight patients with hepatocellular carcinoma from March 2011 to September 2014 in our hospital were enrolled and randomly divided into two groups. Twenty- nine patients of control group were treated with TACE, while patients of observation group were treated with oxaliplatin combined with TACE. Serum tumor necrosis factor-α （TNF-α）, alpha fetal protein （AFP）, white blood cell （WBC）, carcino embryonic antigen （CEA） level and tumor diameter were detected at baseline and after two weeks of treatment. Total effective rate and adverse reactions after chemotherapy were recorded. In addition, patient＇s quality of life and satisfaction were analyzed. Results TNF-a, AFP, CEA level and tumor size of observation group were decreased after treatment, which showed significant difference with those of control group （P〈0.01）. However, WBC had not showed marked change after treatment between two groups. Moreover, total effective rate, quality of life, patient satisfaction of observation group were higher than those of control group, and incidence of adverse reactions in observation group was much lower than that in control group. The differences were statistically significant （P〈0.05）. Conclusion Oxaliplatin combined with TACE could improve total effective rate, patients＂ quality of life, patient satisfaction, and reduce incidence of adverse reactions, which showed safety and effectiveness. The therapeutic schedule is worth of being popularized in clinical application.
出处
《肝脏》
2015年第4期281-284,共4页
Chinese Hepatology
